A Phase 4 interventional study of Esomeprazole Magnesium and Lansoprazole in Heartburn and Gastroesophageal Reflux Disease, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-21.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing esomeprazole in Heartburn — none open to participants now, none under way, none of them phase 3. Esomeprazole · Heartburn.
Among the 19 studies testing esomeprazole in Heartburn, this one is the 10th largest by enrollment, is one of 3 that started in 2002, is one of 15 in phase 4, and was the 10th registered.
154 studies on the registry are indexed under Heartburn; 12 are open to participants now.
Browse Heartburn studies →None of the 19 studies testing esomeprazole in Heartburn is open now. The open studies under Heartburn, anywhere →
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 8 Heartburn studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2002.
This study's enrollment of 248 is above the median of 100 across 127 interventional studies indexed under Heartburn.
Median enrollment 248 across the 19 interventional studies. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 5 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
24 studies in Heartburn by AstraZeneca: none open now, none under way, none of them phase 3. Of 24 finished, 8 (33%) have results posted.
Among the 24 studies in Heartburn by AstraZeneca, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2002, is one of 12 in phase 4, and was the 12th registered.
AstraZeneca’s Heartburn studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing esomeprazole in Heartburn, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 24 in Heartburn:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A double-blind study comparing Esomeprazole Magnesium 40 mg once daily and Lansoprazole 30 mg twice daily to control the symptoms in patients with gastroesophageal reflux disease (GERD) with continued heartburn symptoms with a course of therapy of 30 mg twice daily Lansoprazole.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40mg once daily
Drug: Esomeprazole Magnesium
30mg twice daily
Drug: Lansoprazole
40mg once daily
Also known as: Nexium
30mg twice daily
Also known as: Prevacid
To compare the clinical efficacy of esomeprazole magnesium 40mg once daily versus lansoprazole 30 mg twice daily in symptom control of heartburn in subjects with heartburn symptoms resistant to 30 mg once daily therapy of lansoprazole.
Time frame: Heartburn symptoms collected on diary card daily
To compare efficacy of esomeprazole magnesium 40mg daily vs lansoprazole 30 mg twice daily in symptom control of acid regurgitation, epigastric pain, and night-time heartburn in subjects with GERD symptoms resistant to 30 mg daily therapy of lansoprazole
Time frame: Heartburn symptoms collected on diary card daily
To evaluate the use of supplementary antacids (as heartburn rescue therapy) in subjects treated with esomeprazole magnesium 40 mg once daily versus lansoprazole 30 mg twice daily
Time frame: Heartburn symptoms collected on diary card daily
To assess tolerability of esomeprazole magnesium 40 mg twice daily versus lansoprazole 30 mg twice daily.
Time frame: Ongoing Adverse event collection
No study locations are listed for this record.
The record gives a start of Jun 2002, a primary completion of Feb 2003 and a completion of Feb 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole